echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Anti-CD47 / PD-L1 Bispecific Antibody Clinical Trials: The first patient in China has entered the group.

    Anti-CD47 / PD-L1 Bispecific Antibody Clinical Trials: The first patient in China has entered the group.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Although immune checkpoint inhibitors are treated more than?? There are encouraging results in tumors, but some patients have developed drug resistance and the efficacy of immunocheckpoint inhibitors needs to be further improved, so the development of the next generation of anti-tumor immuno-specific antibodies is of great value, and CD47 is one of the most promising targets in cancer immunotherapy.
    Biopharmaceuticalcompany Innoventannounc today announced that the Phase I clinical trial (CIBI32A101) of recombinant anti-CD47/PD-L1 bispecific antibodies (IBI322) has officially begun and the first patients in China have entered the group.
    CIBI322A101 is a Phase Ia/Ib clinical study conducted in China whose primary purpose was to assess the safety, tolerance and anti-tumor efficacy of IBI322 in patients with advanced malignancies with standard treatment failures.
    IBI322 is a recombinant anti-CD47 / PD-L1 bispecific antibody that blocks the PD-1 / PD-L1 and CD47 /SIRP-alpha pathways.
    preclinical studies show that IBI322 can effectively block CD47-SIRP-alpha interactions and induce macrophages to devour CD47-positive tumor cells.
    on the other hand, IBI322 effectively blocks the binding of PD-1 to PD-L1 and activates CD4-positive T lymphocytes.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.